Ivonescimab
As of the edition of 20 October 2026, Ivonescimab is an antibody: in active development; acts on CD274.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 164, 3 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Skin and connective tissue; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | Q9NZQ7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 0 | 4 | 0 |
| Phase 1 | 10 | 2 | 8 | 0 |
| Phase 2 | 133 | 6 | 122 | 3 |
| Phase 3 | 16 | 0 | 16 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 164 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Akesobio | Lead sponsor of trials | 2019 to now |
| Akeso | Lead sponsor of trials | 2020 to now |
| Summit Therapeutics | Lead sponsor of trials | 2023 to now |
| Jiangsu Alphamab Biopharmaceuticals | Lead sponsor of trials | 2025 to now |
| Shanghai JMT-Bio | Lead sponsor of trials | 2025 to now |
| MediLink Therapeutics | Lead sponsor of trials | 2025 to now |